Results - Announcements
Symbiotec Pharmalab Ltd share price rallied 19.10% to Rs 1513.65 after the company's net profit jumped 267.85% to Rs 51.72 crore, while revenue from operations increased sharply by 28.32% to Rs 279.93 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.54%. It has marginally improved by 2.89% over last one week and moved up slightly by 3.43% in last one month while the market capitalization of Symbiotec Pharmalab Ltd has remained flat
Profit before tax (PBT) of Symbiotec Pharmalab Ltd stood at Rs 64.04 crore in Q2 FY27, surging by 91.34% year-on-year, and jumping 265.32% quarter-on-quarter. EBITDA came in at Rs 91 crore, expanding by 82.33% YoY and rallying 103.79% sequentially.
Total expenses saw a slight increase of 7.96% to Rs 210.29 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 79.62 crore, inching up 5.37% YoY, while employee benefits expense was at Rs 46.96 crore, ticking higher by 1.16% YoY.
For FY26, revenue from operations grew 15.65% to Rs 869.15 crore, while net profit improved by 13.54% to Rs 109.9 crore, compared to previous FY. EBITDA witnessed a strong improvement of 20659% to Rs 234.74 crore, and PBT saw a minor gain of 4.34% to Rs 153.36 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 174.59 crore in FY26, as against Rs 47.26 crore in FY25.